NCT02629393: A reported trial by Origin Biosciences
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02629393 |
|---|---|
| Title | A Phase 2/3, Multicenter, Multinational, Open Label Study to Evaluate the Efficacy and Safety of ORGN001 (Formerly ALXN1101) in Neonates, Infants and Children With Molybdenum Cofactor Deficiency (MOCD) Type A |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | May 31, 2016 |
| Completion date | Sept. 30, 2022 |
| Required reporting date | Sept. 30, 2023, midnight |
| Actual reporting date | Aug. 10, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |